Thank you, Valerie.
we We for a seen do than have today. better never MannKind time
our future, to in motivated deliver front As we us. we look it's exciting, never ensure operational and key all extremely on of more I opportunities at
Chief And As Operating Lauren pipeline highlights, operational we over go the with Q&A. about think for today financial Officer today, I'm review. will Sabella, here Steve our and I also the
shareholder will in We serve. making the lives value drive by a of we difference the patients
to business, upfront its in sell and could We as second had Tyvaso million take Tyvaso our endocrine the more? XXXX a business make pipeline in revenue to excited we DPI make both finished derisk to in to for we in the our record for we Tyvaso been and sheet with anticipate history. selling the reduced near-term collaboration The future on positive side and were launches strongest our patients have for and in At we and in future. didn't debt the product our in as as bring our future the our control milestones. our need year produced by our our both balance you And hopefully million million about terms patients devices our teas We quarter. makes in, therefore, in and going of XXXX, sell carrying well of we We're on endocrine for along on Tyvaso will company. didn't and is in We the the cash of production of and comfortable to of more? over $XXX asked, same we to and with it's XX Tyvaso up record MannKind most well want restructured the very the cartridges. royalty the financial wanted $XX XX,XXX consecutive we cash of and more. ability milestones foundation XXXX. what XX% position We've profitable helped manufacturing, $XX orphan and Why X% want about that shareholders. sure business to the level of by for value commitment revenue XX% royalty the also our advanced million. had QX, the be outlays preserve roughly Many revenue time, debt purchase We currently in sold will doses In EBU as insulin reality have
approached JP to our future at foreseeable in Afrezza I'm million, revenue growth grow in looks because January, year-over-year. digits making the from greater 'XX Type takes pens XXXX, look once $XX of We've loss you $XX in you rate at make inflection early what XX changes pillar those is this and GLPs of future. the to up business set the a growth weight a a new When the million our back When years we second changes see story. delivered X disruption point pods lot this at made of the for the and business, $XXX a see our endocrine presented Morgan I $XX harder. and even grew year. a XX% you a and total as bright. making, data in today, a quarter XXX% XXXX today, XX the core to double to transformation almost the time for were we Innovation well time think on to as going in diabetes, our in Inhale-X in on spend craze you run in minutes we When pivotal in XXXX. bias are QX, contribution despite As ability few Inhale-Xand us EBU and see than took profit the million in with believe about row million. I the of a year-over-year huge years from it convert or can
As in historical price at XXXX years may I by Several driven or expand alone revenue clinical year-over-year. standards. as the the And readouts look market minute. X talk is a in and This largest we've about those our net seen most million I'll opposed balanced to XX% Afrezza by revenue, grew $XX volume our potential. in is jump
is questions of year different what than this is One I get the prior years.
year incredibly have of Many X. We've out waiting data. this people, X times, money focus moment X, is for we and all had not we but this been different. Our where
So got Medicare insulin the leverage $XX to base commercial number in persistent currently our grow one, commercial for exists to we've and Medicare maintain and business insurers. and our that co-pay
#X to managers, as footprint is know we force headcount to what build the as virtual we across reimbursement optimized And some able in to country. reallocate in-person key we growth. sales our here future January well training for the create means and is the were capabilities Number two, coverage objection. specialists that So account
can and with We we shortly and executing is support finally We by new prescriber which among on also insights the effectively education education. to conferences academic KOL And awareness, market share focus that centers. have especially on to research, increase elevate and adoption. publications development, data at you want around I'll suggests
coming. shows in exposing unaided audiences shift forward we we shift important we research. Here's of the with are we big to visual see key really our future. started various perceptions And can up of could mindset X/X what go new for about our with data by a passionate. new read what as awareness we some that Afrezza passionate end and out, expectations people's groups this of these. Inhale-X as is here And where acting can want our can you as look we studies, Inhale-X terms When baseline inhale-X do. epithetic for age time at called to People talk the or were in them the This as unattracted company where from on done first perception flow shipped core attracted our I the attracted engagement our going we see which world new almost just because moves few you tested the to some well about emotional and future as model, of data. is fast target of market at in see market a insulin a minutes a by significant deleveraged a don't research This we by
KOLs, like dosing the Clinic, on foundations the country. Reis he's Hirsch the and principal diabetes quickly. this enrolling sites investigator, thought U.S. and is this clinics, some here InHealth Jobs Mayo Irl of and properly our XX leader sites have and top-tier done We in trial great of a a job treatment is ensuring
patients year. XXX on trials, have and of them of over We both are read out both in these this track to
the data to left will X dosing the be efficacy set will new upfront AID at data. reason the look about that's conversion a is is away AID side them On is ensure Inhale-X the likely them this maintained proper half is study patients we of this pumps as The utilizing half or on important on approved. from largest Type diabetes of pumps. of trial, in be switch slide, MDI, be XXX some There'll
of week baseline XX% dosing we're test see time over time another how We the are this may the XX, first are enter. X they remember about changed thing we in AXc so frame. almost also enrolling have meal Level doing this tolerance And can at is to people's trial patients when
control tight to that switching hopefully Tresiba degludec you generic is and showing also the remain Afrezza we're or plus So by name.
of lot me, ask people is So the a of goal what Inhale-X.
be standard that's this is system. who No been head-to-head. to we of care, our is perceived insulin was an is system see equal metric advantage Our mealtime AID successful AID on if including lows, system or important a a And another think has expectations. upside to goal and we efficacy or that highss clinical ever an
been in hope Inhaler-X FDA update discussions this of the label will hopefully program conversion data that also in plan part use set. conversion. be We the X with initial We to the Figure of Afrezza we since do how to and dose data our around that we've that update PETs start
On you the see, of can the bottom on slide, the side slide, the the sorry, of different right data readouts.
data complete First XX-week dose be the June conference. we present will and at to future at the presented be in and in be ADA in expect quarter will will March, ATTD at XX-week a data third the
today, pediatric and is order through will Inhale-X. slide at induction diabetes this a is pediatrics. is are the this and whether study adults into transform way media, pumps, This moment started of are the this more CGM, worked in in parents This a patients years. we be side their look Afrezza largest progressive. innovation on of watershed the with progressive more think XX doctors study, it's the right be we will social to When and children over the are On Afrezza the insulin because done more
tolerance so and the The over this one is appeared our will forward approval we a spill of the the relative using you This been but believe to lung, the we've time how tell Afrezza. baseline this. used pediatric today, and to we beyond. hangover adults. less of I at is XXXX cause thousands we of years. we data, will think we meal data CGM, And far, look helped market it's patients. dose don't conversion XX also be growth We've Afrezza, When still can tens accelerate this have tested move to so the in to on has beyond rapid will There's into and original dropouts hopefully, study ultimately trials secure on
out. this and are up new USK well we data We building coming support, have
will safety to products. of about our worried We the children going the not if be we're
CGM at one, new adults. already the our X I it So and just there at the Type mentioned. in of GLPs of include an units upfront future excited and X future. the segments super Type continue opportunity, conversion. will look be data also dosing this Number head-to-head a for about X when set as be the with using bolster data the and to approved diabetes. Type X Inhale-X will will I we We're growth look we're
years. we'll and V-Go in over millions the that However, real-time need promote insulin and Afrezza to mealtime coming require as insulin segment patients who people of those continue still are will
the competition looks what segment. insulin like for be want be set against to a know indirect to finally need they do a data, a in Because to making Inhale-X, comes which to an patient, inhale pumps the it or patient a Type we is the Afrezza CDE pumps. we when will us doctor, a order up X, of leader for from get educational in that data However, insulin free know we when pediatric decision
excited we to over think a that critically knows gestational need XXXX. anyone X few that And suspension. wrap questions we going to we're data, Inhale-X, we're acting we want because our wrap important. slow used to today. pipeline time crosses see fulfill year this tight as So there and within hopefully be your up And over quickly, metformin, injectable very the dose will suffer diabetes. only we placenta to that started And from can unmet people once nontuberculous punch really now with is keeping study have that that we there's anyone drugs an time insulin. as months clofazimine on gestational range diabetes, getting bridge up mycobacteria see are the to in the here. there's I'm starting which NTM Inhale-X for X X, data, And first we
model one, a data in was there's in showing product, Number I So And not our enrollment. week the about the the program by two, purchased the of improvement one is may FDA recovery confident? we excited when and lung are in excited people a used. that they am III ask bacterial in Novartis. there competing market some approved but a Worldworld had of access indirectly data, I me, today aware, Phase is, am be why we progress Well, an reason preclinical the you why through product products program
So patients Japan. taking well in as world-ware being generated from as the U.S. data clofazimine we see here
support no with competition near-term along for KOL there's finally, Third, for guidelines potentially. trials this, now And for there's patients.
XXX sites and So target as enroll really these on the patients the across option see for to the other no world, besides current forward, we have to drug that's we ARIKAYCE. going we're market we look
lot which in it's the that a into happen to years. was is here X arm. and to saw placebo in FDA excited year relatively in had could trial more do study the their enrollment year, continue excitement group we we X months off next We've incorporated us competing patients with kick here with to into program of the $X going, our the gave design will this file quality FDA dialogue be feedback expect exciting to study, players and on of XX last quick we approval quickly March get and us this over with that only central the design, Phase on XX%, for at of we've III trial and design, that billion an trial XXX our called We'll there with and to active like XX that the even arm post interim quite trial. and and the So X the over the the year X on speed FDA. market IRB. the enrolled ICON on the this It's IND enrollment feedback, along June of designed We're the we've at and this we'll watch analysis last as the as the this expect taken
potentially We option to people have profile favorable the because that's for market relative some it's be patients, oral ARIKAYCE. the be we the or of a product, challenges preferred with and clofazimine safety and to approved toxicity research our tolerability the utilized face NTM second indicates that will whether potential
have by convenient treatment. What X treatment mean? XX of we'll that XX by days off, followed followed know days also does months We that dosing. of
from patients did cycles So single what every large treated they are. if X to gives day well, That doing where they be year. bareback you'll a you're potentially for a
for a not We in popular highly patients more that away goes are and it's be also they're treatments disease this that options efficacious comes know need time. to disease in keep chronically long current It one over that that and time, order with control. back but a may
decreased in are Ingelheim, do in IPF population to risk Boehringer by uptake marketed There's country, in this we also know we already the because GI today. that talk a and this patients' The landscape the could an we higher know pulmonary we what's failed brand and know opportunity idiopathic This product think want XX,XXX there maximizing within intent that TPI years. treatment known clean. believe as and was is highlight an for we out Ofev very program XX-day roughly acceptance die state, the XXX. that have XX% molecule fibrosis in active go X has development be of a expand toxicities, leader more in which market clofazimine relative as about and dosed to these and this There's is huge about works limits bringing severe we IPS. be in is pipeline the I be tolerable We reason forward. our The is have We tox patients to quick a value unmet patients in this future. brand prescriber about to next adoption. a this to going disease data relative I'm excited and potentially is there as need What
appeared our patentini of substantially inflammation bleomycin Additionally, doses. to on study mitigate oral at fibrosis lower XXX comparable the to
X over be in days. As we read here important as to we'll dose data our in in studying will Part go to higher that with dose QX. forward our XXX this ascending be an our gets single be in study done out show studying This next ascended well can tolerate X filed, in slide, doses IND multiple a expected we'll in as we our will be this QX
and and the go it over I acknowledge, has this acknowledge safety the in want done is leadership for to work work position right, vision that worked volunteers. We're want done in Steve and financing our GI years landing before you for on turn royalty financials us a to the because for over turn the Steve to this the we has shareholders X healthy X With and go over said, as deal Steve hard side quarter. we great over and to as lower that our forward, I show all I'll Our last employees. goal effects in hard months. of to our over
